NanoViricides, Inc. (NYSE American: NNVC) announced it has applied to the Democratic Republic of Congo’s regulatory agency for approval to begin a Phase II clinical trial evaluating its NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company has retained Om Sai Clinical Research Private Limited as the contract research organization, with drug supplies already in the DRC.
NV-387 is an orally administered broad-spectrum antiviral designed to target host-side mechanisms that viruses rely on to infect cells, which the company believes may reduce the likelihood of viral resistance. The planned study builds on NanoViricides’ ongoing Phase II Mpox trial in the DRC and comes as the company seeks to address an outbreak that, according to the release, has resulted in more than 930 deaths and nearly 2,400 confirmed cases since May. The company believes NV-387’s oral formulation could offer logistical advantages over infusion-based therapies in resource-limited settings and, if successful, could support development of a broad-spectrum treatment for Ebola and other filoviruses.
The significance of this announcement lies in the potential for an oral antiviral to improve treatment access in regions with limited healthcare infrastructure. Current Ebola treatments often require intravenous administration, which can be challenging in remote areas. An oral formulation could simplify logistics, reduce the need for trained medical personnel, and enable earlier intervention. Additionally, NV-387’s broad-spectrum mechanism may provide a therapeutic option for multiple filoviruses, addressing a critical gap in pandemic preparedness.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, targets respiratory viruses including RSV, COVID-19, and influenza, as well as poxviruses and filoviruses. The company's technology is based on intellectual property licensed from TheraCour Pharma, Inc. More information is available at www.nanoviricides.com.
For the full press release, visit https://ibn.fm/tmrCX. The latest news and updates relating to NNVC are available at https://ibn.fm/NNVC.
